

Chemicals/Finland, July 21, 2022 Company update

Continued progress

Exel's Q2 results topped estimates and confirmed the company is advancing again after the recent profitability issues in the US.

Absolute profitability topped the previous record

Exel's top line grew 13.5% y/y to EUR 38.1m vs the EUR 36.8m/35.7m Evli/cons. estimates. Wind power customers developed soft relative to our estimate due to China and the local policies, but the shortfall was more than made up by Transportation where revenue grew by EUR 4.4m y/y to EUR 7.2m thanks to released pent up demand after the pandemic. The orders were attributable to old applications like train panels as well as a new aerospace application in North America, on the details of which Exel will elaborate later this year. Exel can already produce the application profitably even though it is only in the initial phases of its lifecycle. Q2 adj. EBIT reached EUR 3.1m, compared to the EUR 2.4m/2.2m Evli/cons. estimates. The 8.2% adj. EBIT margin was not bad, but Exel is still able to do better than that in the long-term assuming growth continues and the US unit keeps improving.

Progress is set to continue

The US unit has already improved a lot in recent quarters yet still has EBIT upside potential. This is also reflected by the EUR 37.0m order intake, which developed flat q/q but declined by 15% y/y as there were certain US Wind power orders last year which were later cancelled due to production challenges. The Q2 report confirmed Exel's continued progress on its long-term track especially in that the company can find suitable high-volume customers and is not overly reliant on any one industry or application. The inflationary environment is not a major challenge given Exel's niche position in the value chain. Exel left its guidance unchanged for now due to the well-known global uncertainties, however an upgrade seems likely in the months ahead.

Valuation is unchallenging as potential materializes

We make only very marginal updates to our estimates. We expect 10% growth for this year while we estimate a 7.4% adj. EBIT margin. The EUR 11m adj. EBIT translates to a valuation multiple of 10x, which would continue to decrease to 8x EV/EBIT on our FY '23 estimates. We retain our EUR 8.5 TP and BUY rating.



Share price, EUR (Last trading day's closing price)	6.58
Target price, EUR	8.5
Latest change in recommendation	20-Jul-21
Latest report on company	02-May-22
Research paid by issuer:	YES
No. of shares outstanding, '000's	11,897
No. of shares fully diluted, '000's	11,897
Market cap, EURm	78
Free float, %	100.0
Exchange rate EUR/USD	1.00
Reuters code	EXL1V.HE
Bloomberg code	EXL1V FH
Average daily volume, EURm	0.1
Next interim report	03-Nov-22
Web site	www.exelcomposites.com
Analyst	Joonas Ilvonen
E-mail	joonas.ilvonen@evli.com
Telephone	+358 44 430 9071

■ BUY ☐ HOLD ■ SELL

KEY FIGL	JRES									
	Sales EURm	EBIT EURm	EBIT %	FCF EURm	EPS EUR	P/E (x)	EV/Sales (x)	EV/EBIT (x)	FCF yield %	DPS EUR
2020	108.6	9.4	8.7%	0.5	0.45	16.4	1.1	12.5	0.6	0.20
2021	134.4	3.7	2.8%	-6.2	0.14	57.0	1.0	34.9	-6.5	0.20
2022E	147.8	8.7	5.9%	5.7	0.68	9.7	0.8	12.7	7.3	0.25
2023E	158.2	13.4	8.5%	7.6	0.80	8.2	0.7	7.9	9.7	0.30
2024E	166.1	16.6	10.0%	10.3	1.00	6.6	0.6	6.0	13.2	0.32
Market ca	p, EURm		78 G	earing 2022E,	0/0		89.0 CAGR	EPS 2021-2	4, %	93.2
Net debt 2	2022E, EURm		33 P	rice/book 2022	2E		2.1 CAGR	sales 2021-	24, %	7.3
Enterprise	value, EURm		111 D	ividend yield 2	2022E, %		3.8 ROE 2	8 ROE 2022E, %		
Total asse	ts 2022E, EURr	n	125 Ta	ax rate 2022E, % 24.6 ROCE 2022E, %						10.5
Goodwill 2	2022E, EURm		13 E	quity ratio 202	22E, %		0.4			



Chemicals/Finland, July 21, 2022 Company update

Estimates and peer group multiples

Exel Composites	2019	2020	Q1'21	Q2'21	Q3'21	Q4'21	2021	Q1'22	Q2'22	Q3'22e	Q4'22e	2022e
Buildings and infrastructure	23.5	23.5	7.0	9.5	8.1	8.4	32.9	7.7	8.9	8.3	8.1	33.0
Equipment and other industries	18.6	19.5	5.6	5.2	5.4	7.1	23.4	7.4	5.9	6.0	7.6	26.8
Wind power	23.6	28.1	7.4	7.8	8.6	8.3	32.1	6.8	6.5	8.0	7.2	28.5
Machinery and electrical	14.4	15.5	3.6	4.3	4.8	4.9	17.6	4.3	5.3	5.1	5.1	19.7
Transportation	13.1	10.2	2.5	2.7	2.1	2.9	10.2	3.1	7.2	5.3	5.1	20.7
Defense	2.3	5.3	2.2	1.8	2.2	2.5	8.7	2.1	1.6	2.3	2.8	8.8
Telecommunications	8.2	6.5	2.5	2.3	2.3	2.3	9.5	2.8	2.8	2.4	2.4	10.5
Revenue	103.8	108.6	31.0	33.5	33.4	36.5	134.4	34.2	38.1	37.5	38.2	147.8
y/y change, %	7 %	5 %	11 %	23 %	28 %	33 %	24 %	10 %	14 %	12 %	5 %	10 %
Adjusted EBIT	7.2	9.7	2.5	2.5	0.1	1.0	6.0	2.2	3.1	2.7	3.0	11.0
EBIT	5.1	9.4	2.4	2.4	-1.7	0.6	3.7	0.0	3.0			8.7
-margin, %	6.9 %	8.9 %	7.9 %	7.3 %	0.3 %	2.8 %	4.5 %	6.4 %	8.2 %	7.2 %	7.9 %	7.4 %
-margin (reported), %	4.9 %	8.7 %	7.8 %	7.0 %	-5.1 %	1.8 %	2.8 %	0.1 %	7.9 %			5.9 %

Source: Evli Research

	MCAP		EV/EBITDA			EV/EBIT			EBIT-%	
EXEL COMPOSITES PEER GROUP	MEUR	22	23	24	22	23	24	22	23	24
Gurit Holding	443	12.5x	9.1x	7.8x	18.7x	13.4x	11.4x	5.7 %	7.0 %	7.7 %
Hexagon Composites	570							-7.6 %	-4.0 %	0.1 %
Hexcel	4723	18.4x	14.3x	12.5x	34.2x	22.6x	18.8x	10.4 %	13.7 %	15.2 %
Avient	3829	8.4x	7.8x	7.4x	11.1x	10.1x	10.0x	9.4 %	10.3 %	11.0 %
SGL Carbon	819	7.2x	6.6x	5.9x	12.9x	10.9x	9.7x	7.4 %	8.4 %	8.8 %
TPI Composites	443	18.7x	8.9x	5.6x		23.1x	9.3x	-1.2 %	1.8 %	4.0 %
Peer Group Average	1804	13.0x	9.3x	7.9x	19.2x	16.0x	11.8x	4.0 %	6.2 %	7.8 %
Peer Group Median	694	12.5x	8.9x	7.4x	15.8x	13.4x	10.0x	6.6 %	7.7 %	8.2 %
Exel Composites (Evli est.)	78	7.2x	5.2x	4.2x	12.7x	7.9x	6.0x	5.9 %	8.5 %	10.0 %
Exel Composites prem./disc. to peer median		-43 %	-41 %	-43 %	-20 %	-41 %	-40 %	-10 %	10 %	22 %

Exel Composites prem./disc. to peer median

Source FactSet, Evli Research

Chemicals/Finland, July 21, 2022 Company update

VALUATION RESULTS	BASE CASE DETAILS	VALUATION ASSUMPTIONS	ASSUMPTIONS FOR WACC	
Current share price	6.58 PV of Free Cash Flow	84 Long-term growth, %	1.5 Risk-free interest rate, %	2.25
DCF share value	12.92 PV of Horizon value	108 WACC, %	8.5 Market risk premium, %	5.8
Share price potential, %	96.3 Unconsolidated equity	0 Spread, %	0.5 Debt risk premium, %	3.3
Maximum value	14.2 Marketable securities	16 Minimum WACC, %	8.0 Equity beta coefficient	1.00
Minimum value	11.8 Debt - dividend	-54 Maximum WACC, %	9.0 Target debt ratio, %	10
Horizon value, %	56.3 Value of stock	154 Nr of shares, Mn	11.9 Effective tax rate, %	21

DCF valuation, EURm	2021	2022E	2023E	2024E	2025E	2026E	2027E	2028E	2029E	2030E	2031E	Horizon
Net sales	134	148	158	166	171	175	179	182	186	190	193	196
Sales growth, %	23.7	10.0	7.0	5.0	3.0	2.5	2.0	2.0	2.0	2.0	1.5	1.5
Operating income (EBIT)	4	9	13	17	18	18	19	20	21	22	22	22
Operating income margin, %	2.8	5.9	8.5	10.0	10.5	10.5	10.5	11.0	11.5	11.5	11.5	11.5
+ Depreciation+amort.	8	7	7	7	7	7	7	7	7	7	7	
EBITDA	12	15	20	24	25	26	25	27	28	29	29	
- Paid taxes	-3	-2	-3	-4	-4	- 5	-5	-5	- 5	- 5	-5	
- Change in NWC	- 5	-2	-1	-1	-1	-1	0	0	0	-1	0	
NWC / Sales, %	12.7	12.8	12.8	12.8	12.9	12.9	12.9	12.9	12.9	12.9	12.9	
+ Change in other liabs	0	0	0	0	0	0	0	0	0	0	0	
- Operative CAPEX	-10	-6	-6	-6	-6	-7	-7	-7	-7	-7	-7	
opCAPEX / Sales, %	8.2	4.9	4.7	4.5	4.4	4.4	4.0	4.0	4.0	4.0	3.9	
- Acquisitions	0	0	0	0	0	0	0	0	0	0	0	
+ Divestments	0	0	0	0	0	0	0	0	0	0	0	
- Other items	0	0	0	0	0	0	0	0	0	0	0	
= FCFF	- 5	5	9	12	13	14	14	15	15	16	16	235
= Discounted FCFF		5	8	10	10	10	9	9	8	8	7	108
= DFCF min WACC	•	5	8	10	10	10	9	9	9	8	8	122
= DFCF max WACC	•	5	8	10	10	9	8	8	8	8	7	97

Chemicals/Finland, July 21, 2022 Company update

INTERIM FIGURES

EVLI ESTIMATES, EURm	2021Q1	202102	2021Q3	2021Q4	2021	2022Q1	2022Q2	2022Q3E	2022Q4E	2022E	2023E	2024E
Net sales	31.0	33.5	33.4	36.5	134.4	34.2	38.1	37.5	38.2	147.8	158.2	166.1
EBITDA	4.0	3.9	0.0	4.1	11.9	1.8	4.8	4.3	4.6	15.4	20.4	23.6
EBITDA margin (%)	13.0	11.7	-0.1	11.1	8.9	5.2	12.5	11.5	12.0	10.4	12.9	14.2
EBIT	2.4	2.4	-1.7	0.6	3.7	0.0	3.0	2.7	3.0	8.7	13.4	16.6
EBIT margin (%)	7.8	7.0	-5.1	1.8	2.8	0.1	7.9	7.2	7.9	5.9	8.5	10.0
Net financial items	0.5	-0.5	0.4	0.0	0.4	0.5	1.9	-0.2	-0.2	2.0	-0.8	-0.8
Pre-tax profit	2.9	1.9	-1.3	0.7	4.2	0.5	4.9	2.5	2.8	10.7	12.6	15.8
Tax	-0.9	-0.5	-0.9	-0.2	-2.5	-0.5	-1.0	-0.5	-0.6	-2.6	-3.1	-3.9
Tax rate (%)	30.8	25.4	-68.9	31.2	60.2	104.4	20.0	21.0	21.0	24.6	24.6	24.6
Net profit	2.0	1.4	-2.2	0.5	1.7	0.0	3.9	2.0	2.2	8.1	9.5	11.9
EPS	0.17	0.12	-0.19	0.04	0.14	0.00	0.33	0.17	0.19	0.68	0.80	1.00
EPS adjusted (diluted no. of shares)	0.17	0.12	-0.19	0.04	0.14	0.00	0.33	0.17	0.19	0.68	0.80	1.00
Dividend per share	0.00	0.00	0.00	0.00	0.20	0.00	0.00	0.00	0.00	0.25	0.30	0.32
SALES, EURm												
Exel Composites	31.0	33.5	33.4	36.5	134.4	34.2	38.1	37.5	38.2	147.8	158.2	166.1
Total	31.0	33.5	33.4	36.5	134.4	34.2	38.1	37.5	38.2	147.8	158.2	166.1
SALES GROWTH, Y/Y %												
Exel Composites	11.3	23.3	28.0	32.6	23.7	10.3	13.5	12.2	4.5	10.0	7.0	5.0
Total	11.3	23.3	28.0	32.6	23.7	10.3	13.5	12.2	4.5	10.0	7.0	5.0
EBIT, EURm												
Exel Composites	2.4	2.4	-1.7	0.6	3.7	0.0	3.0	2.7	3.0	8.7	13.4	16.6
Total	2.4	2.4	-1.7	0.6	3.7	0.0	3.0	2.7	3.0	8.7	13.4	16.6
EBIT margin, %												
Exel Composites	7.8	7.0	-5.1	1.8	2.8	0.1	7.9	7.2	7.9	5.9	8.5	10.0
Total	7.8	7.0	-5.1	1.8	2.8	0.1	7.9	7.2	7.9	5.9	8.5	10.0

Chemicals/Finland, July 21, 2022 Company update

INCOME STATEMENT, EURm	2017	2018	2019	2020	2021	2022E	2023E	2024E
Sales	86.3	96.6	103.8	108.6	134.4	147.8	158.2	166.1
Sales growth (%)	18.1	11.9	7.5	4.6	23.7	10.0	7.0	5.0
EBITDA	9.3	7.7	10.7	15.3	11.9	15.4	20.4	23.6
EBITDA margin (%)	10.8	8.0	10.3	14.1	8.9	10.4	12.9	14.2
Depreciation	-3.2	-5.5	-5.6	-5.8	-8.2	-6.7	-6.9	-7.0
EBITA	6.1	2.2	5.1	9.4	3.7	8.7	13.4	16.6
Goodwill amortization / writedown	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBIT	6.1	2.2	5.1	9.4	3.7	8.7	13.4	16.6
EBIT margin (%)	7.1	2.3	4.9	8.7	2.8	5.9	8.5	10.0
Reported EBIT	6.1	2.2	5.1	9.4	3.7	8.7	13.4	16.6
EBIT margin (reported) (%)	7.1	2.3	4.9	8.7	2.8	5.9	8.5	10.0
Net financials	-0.7	-0.5	-1.2	-2.3	0.4	2.0	-0.8	-0.8
Pre-tax profit	5.4	1.7	3.9	7.1	4.2	10.7	12.6	15.8
Taxes	-1.2	-1.3	-1.5	-1.7	-2.5	-2.6	-3.1	-3.9
Minority shares	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net profit	4.2	0.4	2.4	5.4	1.7	8.1	9.5	11.9
Cash NRIs	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Non-cash NRIs	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
BALANCE SHEET, EURm								
Assets								
Fixed assets	16	21	23	30	34	34	34	35
Goodwill	13	13	13	13	13	13	13	13
Right of use assets	0	5	5	3	3	3	4	4
Inventory	12	15	17	16	24	26	28	30
Receivables	15	20	20	21	26	29	31	32
Liquid funds	8	5	7	12	16	17	18	19
Total assets	64	79	85	97	118	125	130	135
Liabilities								
Shareholder's equity	29	26	26	29	31	37	43	52
Minority interest	0	0	0	0	0	0	0	0
Convertibles	0	0	0	0	0	0	0	0
Lease liabilities	0	3	4	2	2	3	4	4
Deferred taxes	0	0	0	0	0	0	0	0
Interest bearing debt	16	30	32	40	50	47	43	37
Non-interest bearing current liabilities	18	18	21	24	32	35	38	40
Other interest-free debt	0	2	2	2	3	3	3	3
Total liabilities	64	79	85	97	118	125	130	135
CASH FLOW, EURm								
+ EBITDA	9	8	11	15	12	15	20	24
- Net financial items	-1	0	-1	-2	0	2	-1	-1
- Taxes	-1	-2	-2	-2	-3	-3	-3	-4
- Increase in Net Working Capital	-3	-4	1	3	-5	-2	-1	-1
+/- Other	1	0	0	0	0	0	0	0
= Cash flow from operations	5	1	8	13	5	13	15	18
- Capex	-3	-10	-8	-13	-11	-7	-7	-8
- Acquisitions	0	0	0	0	0	0	0	0
+ Divestments	0	0	0	0	0	0 6	0	0
= Free cash flow	1	-9	1	0	-6		8	10
+/- New issues/buybacks	-1	0	0 -2	-1	3	0	0	0
- Paid dividend	-1 1	-4		-2 7	-2 9	-2	-3	-4
+/- Other	1 0	9 -3	3 2	7 5	9	-2 2	-3 1	-6 1
Change in cash	U	-3	۷	Э	4	۷	ı	1

Chemicals/Finland, July 21, 2022 Company update

KEY FIGURES	2018	2019	2020	2021	2022E	2023E	2024E
M-cap	48	78	88	94	78	78	78
Net debt (excl. convertibles)	28	29	30	36	33	28	21
Enterprise value	76	107	118	131	111	106	100
Sales	97	104	109	134	148	158	166
EBITDA	8	11	15	12	15	20	24
EBIT	2	5	9	4	9	13	17
Pre-tax	2	4	7	4	11	13	16
Earnings	0	2	5	2	8	10	12
Equity book value (excl. minorities)	26	26	29	31	37	43	52
Valuation multiples			-	-	-		
EV/sales	0.8	1.0	1.1	1.0	0.8	0.7	0.6
EV/EBITDA	9.9	10.0	7.7	10.9	7.2	5.2	4.2
EV/EBITA	34.5	21.0	12.5	34.9	12.7	7.9	6.0
EV/EBIT	34.5	21.0	12.5	34.9	12.7	7.9	6.0
EV/OCF	84.3	12.9	8.8	27.2	8.6	7.3	5.6
EV/FCFF	-6.6	32.5	52.9	-26.0	21.5	11.4	8.3
P/FCFE	-5.5	110.9	179.1	-15.3	13.6	10.3	7.6
P/E	119.0	32.5			9.7	8.2	6.6
r/c P/B		32.5	16.4	57.0	2.1		
•	1.8		3.1	3.0		1.8	1.5
Target EV/EBITDA	0.0	0.0	0.0	0.0	8.7	6.3	5.2
Target EV/EBIT	0.0	0.0	0.0	0.0	15.3	9.6	7.4
Target EV/FCF	0.0	0.0	0.0	0.0	23.3	17.0	11.8
Target P/B	0.0	0.0	0.0	0.0	2.7	2.3	2.0
Target P/E	0.0	0.0	0.0	0.0	12.5	10.6	8.5
Per share measures							
Number of shares	11,897	11,897	11,897	11,897	11,897	11,897	11,897
Number of shares (diluted)	11,897	11,897	11,897	11,897	11,897	11,897	11,897
EPS	0.03	0.20	0.45	0.14	0.68	0.80	1.00
Operating cash flow per share	0.08	0.70	1.12	0.40	1.09	1.27	1.50
Free cash flow per share	-0.73	0.06	0.04	-0.52	0.48	0.64	0.87
Book value per share	2.16	2.21	2.41	2.62	3.10	3.66	4.36
Dividend per share	0.18	0.18	0.20	0.20	0.25	0.30	0.32
Dividend payout ratio, %	535.4	89.2	44.3	143.7	36.8	37.5	31.9
Dividend yield, %	4.5	2.7	2.7	2.5	3.8	4.6	4.9
FCF yield, %	-18.3	0.9	0.6	-6.5	7.3	9.7	13.2
Efficiency measures							
ROE					23.7	23.7	25.0
	1.5	9.2	19.5	5.5	23.7		
ROCE	1.5 4.5	9.2 8.6	19.5 14.4	5.5 5.1	10.5	13.8	15.7
ROCE Financial ratios						13.8	15.7
						13.8	15.7
Financial ratios	4.5	8.6	14.4	5.1	10.5		
Financial ratios Inventories as % of sales	4.5 15.7	8.6	14.4	5.1 17.8	10.5	17.8	17.8
Financial ratios Inventories as % of sales Receivables as % of sales	4.5 15.7 20.8	16.3 19.2	14.4 14.9 19.2	5.1 17.8 19.6	10.5 17.8 19.6	17.8 19.6	17.8 19.6
Financial ratios Inventories as % of sales Receivables as % of sales Non-interest bearing liabilities as % of sales	4.5 15.7 20.8 19.2	16.3 19.2 20.2	14.4 14.9 19.2 22.0	5.1 17.8 19.6 23.8	17.8 19.6 23.8	17.8 19.6 23.8	17.8 19.6 23.8
Financial ratios Inventories as % of sales Receivables as % of sales Non-interest bearing liabilities as % of sales NWC/sales, %	4.5 15.7 20.8 19.2 16.1	16.3 19.2 20.2 14.1	14.4 14.9 19.2 22.0 11.2	5.1 17.8 19.6 23.8 12.7	17.8 19.6 23.8 12.8	17.8 19.6 23.8 12.8	17.8 19.6 23.8 12.8
Financial ratios Inventories as % of sales Receivables as % of sales Non-interest bearing liabilities as % of sales NWC/sales, % Operative CAPEX/sales, % CAPEX/sales (incl. acquisitions), %	4.5 15.7 20.8 19.2 16.1 9.9 9.9	16.3 19.2 20.2 14.1 7.3 7.3	14.4 14.9 19.2 22.0 11.2 11.9	5.1 17.8 19.6 23.8 12.7 8.2 8.2	17.8 19.6 23.8 12.8 4.9	17.8 19.6 23.8 12.8 4.7 4.7	17.8 19.6 23.8 12.8 4.5 4.5
Financial ratios Inventories as % of sales Receivables as % of sales Non-interest bearing liabilities as % of sales NWC/sales, % Operative CAPEX/sales, % CAPEX/sales (incl. acquisitions), % FCFF/EBITDA	4.5 15.7 20.8 19.2 16.1 9.9 9.9 -1.5	8.6 16.3 19.2 20.2 14.1 7.3 7.3 0.3	14.4 14.9 19.2 22.0 11.2 11.9 11.9 0.1	5.1 17.8 19.6 23.8 12.7 8.2 8.2 -0.4	10.5 17.8 19.6 23.8 12.8 4.9 4.9	17.8 19.6 23.8 12.8 4.7 4.7	17.8 19.6 23.8 12.8 4.5 4.5
Financial ratios Inventories as % of sales Receivables as % of sales Non-interest bearing liabilities as % of sales NWC/sales, % Operative CAPEX/sales, % CAPEX/sales (incl. acquisitions), % FCFF/EBITDA Net debt/EBITDA, book-weighted	4.5 15.7 20.8 19.2 16.1 9.9 9.9 -1.5 3.7	8.6 16.3 19.2 20.2 14.1 7.3 7.3 0.3 2.7	14.4 14.9 19.2 22.0 11.2 11.9 11.9 0.1 2.0	5.1 17.8 19.6 23.8 12.7 8.2 8.2 -0.4 3.0	10.5 17.8 19.6 23.8 12.8 4.9 4.9 0.3 2.1	17.8 19.6 23.8 12.8 4.7 4.7 0.5	17.8 19.6 23.8 12.8 4.5 4.5 0.5
Financial ratios Inventories as % of sales Receivables as % of sales Non-interest bearing liabilities as % of sales NWC/sales, % Operative CAPEX/sales, % CAPEX/sales (incl. acquisitions), % FCFF/EBITDA	4.5 15.7 20.8 19.2 16.1 9.9 9.9 -1.5	8.6 16.3 19.2 20.2 14.1 7.3 7.3 0.3	14.4 14.9 19.2 22.0 11.2 11.9 11.9 0.1	5.1 17.8 19.6 23.8 12.7 8.2 8.2 -0.4	10.5 17.8 19.6 23.8 12.8 4.9 4.9	17.8 19.6 23.8 12.8 4.7 4.7	17.8 19.6 23.8 12.8 4.5 4.5

EVLI EQUITY RESEARCH

EXEL COMPOSITES

Chemicals/Finland, July 21, 2022 Company update

COMPANY DESCRIPTION: Exel Composites manufactures composites profiles for various demanding, mainly industrial end-use, applications. Exel's customer base includes companies operating in industries such as wind energy, transportation and telecommunications. Exel Composites is one of the largest manufacturers of pultruded composites profiles globally and currently operates eight manufacturing plants on three continents.

INVESTMENT CASE: Our positive view is based on good long-term composites demand outlook, coupled with the fact that Exel Composites' current manufacturing footprint could support annual revenue in the EUR 150m ballpark i.e. there's still plenty of room to improve delivery volumes. Exel's rather high fixed cost base translates to meaningful operating leverage, and thus higher revenues should lead to improving operating margins. The company is also progressing well with its cost savings program. Operating profit could further significantly improve if good execution continues. Recently the wind energy sector has provided great lift for volumes; other attractive applications include e.g. transportation industry profiles.

OWNERSHIP STRUCTURE	SHARES	EURm	0/0
Sijoitusrahasto Taaleritehdas Mikro Markka	800,000	5.264	6.7%
OP-Finland Small Firms Fund	590,119	3.883	5.0%
Ilmarinen Mutual Pension Insurance	496,547	3.267	4.2%
Op-Suomi Mikroyhtiöt -Erikoissijoitusrahasto	420,000	2.764	3.5%
Phoebus Fund	370,000	2.435	3.1%
Säästöpankki Pienyhtiöt	288,710	1.900	2.4%
Nelimarkka Heikki Antero	213,545	1.405	1.8%
Veritas Pension Insurance Company Ltd.	207,479	1.365	1.7%
Säästöpankki Kotimaa	132,680	0.873	1.1%
Sumato Oy	131,821	0.867	1.1%
Ten largest	3,650,901	24.023	31%
Residual	8,245,942	54.258	69%
Total	11,896,843	78.281	100%

EARNINGS CALENDAR	
November 03, 2022	Q3 report
OTHER EVENTS	

COMPANY MISCELLANEOUS	
CEO: Riku Kytömäki	Mäkituvantie 5 01510 Vantaa
CFO: Mikko Kettunen	Tel: +358 20 7541 200
IR: Noora Koikkalainen	

Chemicals/Finland, July 21, 2022 Company update

DEFINITIONS

P/E	EPS	
111	LI J	
Price per share Earnings per share	Profit before extraord. items and taxes—income taxes + minority interest Number of shares	
P/BV	DPS	
Price per share Shareholders' equity + taxed provisions per share	Dividend for the financial period per share	
Market cap	OCF (Operating cash flow)	
Price per share * Number of shares	EBITDA – Net financial items – Taxes – Increase in working capital – Cash NRIs ± Other adjustments	
EV (Enterprise value)	FCF (Free cash flow)	
Market cap + net debt + minority interest at market value – share of associated companies at market value	Operating cash flow – operative CAPEX – acquisitions + divestments	
EV/Sales	FCF yield, %	
Enterprise value Sales	Free cash flow Market cap	
EV/EBITDA	Operative CAPEX/sales	
Enterprise value Earnings before interest, tax, depreciation and amortization	Capital expenditure – divestments – acquisitions Sales	
EV/EBIT	Net working capital	
Enterprise value Operating profit	Current assets – current liabilities	
Net debt	Capital employed/Share	
Interest bearing debt – financial assets	Total assets – non-interest bearing debt Number of shares	
Total assets	Gearing	
Balance sheet total	<u>Net debt</u> Equity	
Div yield, %	Debt/Equity, %	
<u>Dividend per share</u> Price per share	Interest bearing debt Shareholders' equity + minority interest + taxed provisions	
Payout ratio, %	Equity ratio, %	
Total dividends Earnings before extraordinary items and taxes – income taxes + minority interest	Shareholders' equity + minority interest + taxed provisions Total assets – interest-free loans	
ROCE, %	CAGR, %	
Profit before extraordinary items + interest expenses+ other financial costs Balance sheet total – non-interest bearing debt (average)	Cumulative annual growth rate = Average growth per year	
ROE, %		
Profit before extraordinary items and taxes – income taxes Shareholder's equity + minority interest + taxed provisions (average)		

Chemicals/Finland, July 21, 2022 Company update

Important Disclosures


Evli Research Partners Plc ("ERP") uses 12-month target prices. Target prices are defined by utilizing analytical techniques based on financial theory including (but not limited to) discounted cash flow analysis and comparative valuation. The selection of valuation methods depends on different circumstances. Target prices may be altered on the basis of new information coming to light in the underlying company or changes in interest rates, changes in foreign exchange rates, other securities prices or market indices or outlook for the aforementioned factors or other factors that may change the conditions of financial markets. Recommendations and changes by analysts are available at <u>Analysts' recommendations and ratings revisions</u>.

Investment recommendations are defined as follows:

Target price compared to share price Recommendation

< -10 % SELL -10 - (+10) % HOLD > 10 % BUY

ERP's investment recommendation of the analyzed company is updated at least 2 times per year.



The graph above shows the distribution of ERP's recommendations of companies under coverage in 11th of May 2020. If recommendation is not given, it is not mentioned here.

Name(s) of the analyst(s): Ilvonen

This research report has been prepared by Evli Research Partners Plc ("ERP" or "Evli Research"). ERP is a subsidiary of Evli Plc. Production of the investment recommendation has been concluded on [21.7.2022, 9:15]. This report has been published on [21.7.2022, 9:35].

None of the analysts contributing to this report, persons under their guardianship or corporations under their control have a position in the shares of the company or related securities.

The date and time for any price of financial instruments mentioned in the recommendation refer to the previous trading day's closing price(s) unless otherwise stated in the report.

Each analyst responsible for the content of this report assures that the expressed views accurately reflect the personal views of each analyst on the covered companies and securities. Each analyst assures that (s)he has not been, nor are or will be, receiving direct or indirect compensation related to the specific recommendations or views contained in this report.

Companies in the Evli Group, affiliates or staff of companies in the Evli Group, may perform services for, solicit business from, hold long or short positions in, or otherwise be interested in the investments (including derivatives) of any company mentioned in the publication or report.

Neither ERP nor any company within the Evli Group have managed or co-managed a public offering of the company's securities during the last 12 months prior to, received compensation for investment banking services from the company during the last 12 months prior to the publication of the research report.

ERP has signed an agreement with the issuer of the financial instruments mentioned in the recommendation, which includes production of research reports. This assignment has a limited economic and financial impact on ERP and/or Evli. Under the assignment ERP performs services including, but not limited to, arranging investor meetings or –events, investor relations communication advisory and production of research material.

ERP or another company within the Evli Group does not have an agreement with the company to perform market making or liquidity providing services.

For the prevention and avoidance of conflicts of interests with respect to this report, there is an information barrier (Chinese wall) between Investment

EVLI EQUITY RESEARCH

EXEL COMPOSITES

Chemicals/Finland, July 21, 2022 Company update

Research and Corporate Finance units concerning unpublished investment banking services to the company. The remuneration of the analyst(s) is not tied directly or indirectly to investment banking transactions or other services performed by Evli Plc or any company within Evli Group.

This report has not been disclosed to the company prior to its dissemination.

This report is provided and intended for informational purposes only and may not be used or considered under any circumstances as an offer to sell or buy any securities or as advice to trade any securities.

This report is based on sources ERP considers to be correct and reliable. The sources include information providers Reuters and Bloomberg, stock-exchange releases from the companies and other company news, Statistics Finland and articles in newspapers and magazines. However, ERP does not guarantee the materialization, correctness, accuracy or completeness of the information, opinions, estimates or forecasts expressed or implied in the report. In addition, circumstantial changes may have an influence on opinions and estimates presented in this report. The opinions and estimates presented are valid at the moment of their publication and they can be changed without a separate announcement. Neither ERP nor any company within the Evli Group are responsible for amending, correcting or updating any information, opinions or estimates contained in this report. Neither ERP nor any company within the Evli Group will compensate any direct or consequential loss caused by or derived from the use of the information represented in this publication.

All information published in this report is for the original recipient's private and internal use only. ERP reserves all rights to the report. No part of this publication may be reproduced or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, or stored in any retrieval system of any nature, without the written permission of ERP.

This report or its copy may not be published or distributed in Australia, Canada, Hong Kong, Japan, New Zealand, Singapore or South Africa. The publication or distribution of this report in certain other jurisdictions may also be restricted by law. Persons into whose possession this report comes are required to inform themselves about and to observe any such restrictions.

Evli Plc is not registered as a broker-dealer with the U. S. Securities and Exchange Commission ("SEC"), and it and its analysts are not subject to SEC rules on securities analysts' certification as to the currency of their views reflected in the research report. Evli is not a member of the Financial Industry Regulatory Authority ("FINRA"). It and its securities analysts are not subject to FINRA's rules on Communications with the Public and Research Analysts and Research Reports and the attendant requirements for fairness, balance and disclosure of potential conflicts of interest. This research report is only being offered in U.S. by Auerbach Grayson & Company, LLC (Auerbach Grayson) to Major U.S. Institutional Investors and is not available to, and should not be used by, any U.S. person or entity that is not a Major U.S. Institutional Investor. Auerbach Grayson is a broker-dealer registered with the U.S. Securities and Exchange Commission and is a member of the FINRA. U.S. entities seeking more information about any of the issuers or securities discussed in this report should contact Auerbach Grayson. The securities of non-U.S. issuers may not be registered with or subject to SEC reporting and other requirements.

ERP is not a supervised entity but its parent company Evli Plc is supervised by the Finnish Financial Supervision Authority.

Chemicals/Finland, July 21, 2022 Company update

Contact information SALES, TRADING AND RESEARCH

Equity, ETF and Derivatives Sales		Trading	
Joachim Dannberg Ari Laine Kimmo Lilja	+358 9 4766 9123 +358 9 4766 9115 +358 9 4766 9130	Lauri Vehkaluoto (Head) Pasi Väisänen Antti Kässi Miika Ronkanen	+358 9 4766 9120 +358 9 4766 9120 +358 9 4766 9120 +358 9 4766 9120
Structured Investments		Equity Research	
Heikki Savijoki Aki Lakkisto	+358 9 4766 9726 +358 9 4766 9123	Jonas Forslund Joonas Ilvonen Jerker Salokivi Teemu Reiman	+358 9 4766 9314 +358 44 430 9071 +358 9 4766 9149 +358 40 352 6175
Evli Investment Solutions			
Johannes Asuja	+358 9 4766 9205		



EVLI BANK PLC
Aleksanterinkatu 19 A
P.O. Box 1081
FIN-00101 Helsinki, FINLAND
Phone +358 9 476 690
Fax +358 9 634 382
Internet www.evli.com
E-mail firstname.lastname@evli.com

EVLI BANK PLC, STOCKHOLMSFILIAL Regeringsgatan 67 P.O. Box 16354 SE-103 26 Stockholm Sverige stockholm@evli.com Tel +46 (0)8 407 8000 Fax +46 (0)8 407 8001